Link to the University of Pittsburgh Homepage
Link to the University Library System Homepage Link to the Contact Us Form

Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3)

Weinreb, NJ and Finegold, DN and Feingold, E and Zeng, Z and Rosenbloom, BE and Shankar, SP and Amato, D (2015) Evaluation of disease burden and response to treatment in adults with type 1 gaucher disease using a validated disease severity scoring system (DS3). Orphanet Journal of Rare Diseases.

[img]
Preview
PDF
Published Version
Available under License : See the attached license file.

Download (2MB) | Preview
[img] Plain Text (licence)
Available under License : See the attached license file.

Download (1kB)

Abstract

© 2015 Weinreb et al.Background: GD1-DS3 is an integrated assessment of type 1 Gaucher disease (GD1) burden based on bone, hematologic and visceral domains. We investigated this disease severity scoring system (DS3) methodology for initial assessment, long-term follow-up and evaluation of treatment responses. Methods: We enrolled 133 treated adult GD1 patients. Baseline DS3 scores were calculated near the initial treatment date and patients stratified by severity as marked (DS3 6.00-19.00), moderate (DS3 3.00-5.99), mild (DS3 < 3.00). Follow-up scores were calculated annually. Minimal clinically important improvement (MCII), is defined as {increment}DS3 of -3.1. Results: Patient characteristics: N370S was the most common allele (118 patients had at least one), 52 were N370S/N370S (48/52 were Ashkenazi Jews), N370S/L444P was the most common genotype among non-Jews. Median age of treatment: 45 years; median follow-up: 14 years. Baseline DS3 scores: Patients with marked disease (N = 58; median 7.84) were least likely to be N370S homozygous (19 %) and most likely to have had splenectomy (53 %), early age at diagnosis (median 18 years) and major pre-treatment bone pathology (76 %). Among patients with moderate disease (N = 53; median 4.33), 49 % were N370S/N370S, 15.1 % had splenectomy and 17 % had major bone disease. Median age at diagnosis: 32 years. No patient with mild disease (N = 22; median 2.4) had splenectomy or major skeletal disease. Median age at diagnosis: 40 years. 68 % were N370S homozygous. Response to treatment: Health-state transitions occurred primarily during the early treatment years. At Year 5, among 48 evaluable patients with marked baseline disease, eight were unchanged in severity status whereas 40 had MCII of varying degrees with 11 scored as mild. Among 42 evaluable moderate patients, none worsened, 16 remained moderate and 26 improved to mild. Among 16 evaluable mild patients, 14 remained so and 2 had DS3 scores in the low moderate range. Conclusions: DS3 is effective for assessing disease burden in GD1 and for monitoring response. ERT was associated with MCII in DS3 scores in patients with high severity. Nevertheless, despite better DS3 scores with treatment, GD1 patients especially those with splenectomy and pre-treatment bone pathology, continued to have bone complications.


Share

Citation/Export:
Social Networking:
Share |

Details

Item Type: Article
Creators/Authors:
CreatorsEmailPitt UsernameORCID
Weinreb, NJ
Finegold, DNdnf@pitt.eduDNF
Feingold, Efeingold@pitt.eduFEINGOLD
Zeng, Zzhz43@pitt.eduZHZ43
Rosenbloom, BE
Shankar, SP
Amato, D
Date: 22 May 2015
Date Type: Publication
Journal or Publication Title: Orphanet Journal of Rare Diseases
DOI or Unique Handle: 10.1186/s13023-015-0280-3
Schools and Programs: Graduate School of Public Health > Human Genetics
School of Medicine > Pediatrics
Refereed: Yes
Date Deposited: 16 Aug 2016 16:47
Last Modified: 13 Oct 2017 18:55
URI: http://d-scholarship.pitt.edu/id/eprint/29270

Metrics

Monthly Views for the past 3 years

Plum Analytics

Altmetric.com


Actions (login required)

View Item View Item